IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial
Ideaya Biosciences has dosed the first subject in its Phase I clinical trial of IDE397 plus Trodelvy in patients with methylthioadenosine phosphorylase (MTAP)-deletion bladder cancer. This trial is part of an ongoing IDEAYA-sponsored study that includes a …